Increased risk of internal tumors in DNA repair-deficient xeroderma pigmentosum patients: analysis of four international cohorts.
Internal cancers
Leukemia
Nucleotide excision repair
Transcription-coupled repair
UV-light
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
04 03 2022
04 03 2022
Historique:
received:
16
09
2021
accepted:
30
01
2022
entrez:
5
3
2022
pubmed:
6
3
2022
medline:
14
4
2022
Statut:
epublish
Résumé
Xeroderma pigmentosum (XP) is a rare, autosomal, recessive DNA repair-deficiency disorder with a frequency of 1-3 per million livebirths in Europe and USA but with higher frequencies in isolated islands or in countries with a high level of consanguinity. XP is characterized by high incidence of skin cancers on sun-exposed sites. Recent improvement in life expectancy of XP patients suggests an increased risk of frequently aggressive and lethal internal tumors. Our purpose was to quantify relative risks of internal tumor development for XP patients by tumor type, XP-subtype, patients' ages and ethnicity through comparison with the US general population. We analyzed four independent international well-characterized XP cohorts (from USA, UK, France and Brazil) with a total of 434 patients, where 11.3% developed internal tumors and compared them to the American general population. We also compiled, through PubMed/Medline, a dataset of 89 internal tumors in XP patients published between 1958 and 2020. In the combined 4-XP cohort, relative risk of internal tumors was 34 (95% confidence interval (CI) 25-47) times higher than in the general population (p-value = 1.0E-47) and tumor arose 50 years earlier. The XP-C group was at the highest risk for the 0-20 years old-patients (OR = 665; 95% CI 368-1200; p-value = 4.3E-30). The highest risks were observed for tumors of central nervous system (OR = 331; 95% CI 171-641; p-value = 2.4E-20), hematological malignancies (OR = 120; 95% CI 77-186; p-value = 3.7E-36), thyroid (OR = 74; 95% CI 31-179; p-value = 1.2E-8) and gynecological tumors (OR = 91; 95% CI 42-193; p-value = 3.5E-12). The type of mutation on the XPC gene is associated with different classes of internal tumors. The majority of French XP-C patients (80%) are originated from North Africa and carried the XPC delTG founder mutation specific from the South Mediterranean area. The OR is extremely high for young (0-20 years) patients with more than 1300-fold increase for the French XPs carrying the founder mutation. Because the age of XP population is increasing due to better sun-protection and knowledge of the disease, these results are of particular importance for the physicians to help in early prevention and detection of internal tumors in their XP patients. Few preventive blood analyses or simple medical imaging may help to better detect early cancer appearance in this population.
Sections du résumé
BACKGROUND
Xeroderma pigmentosum (XP) is a rare, autosomal, recessive DNA repair-deficiency disorder with a frequency of 1-3 per million livebirths in Europe and USA but with higher frequencies in isolated islands or in countries with a high level of consanguinity. XP is characterized by high incidence of skin cancers on sun-exposed sites. Recent improvement in life expectancy of XP patients suggests an increased risk of frequently aggressive and lethal internal tumors. Our purpose was to quantify relative risks of internal tumor development for XP patients by tumor type, XP-subtype, patients' ages and ethnicity through comparison with the US general population.
METHODS
We analyzed four independent international well-characterized XP cohorts (from USA, UK, France and Brazil) with a total of 434 patients, where 11.3% developed internal tumors and compared them to the American general population. We also compiled, through PubMed/Medline, a dataset of 89 internal tumors in XP patients published between 1958 and 2020.
RESULTS
In the combined 4-XP cohort, relative risk of internal tumors was 34 (95% confidence interval (CI) 25-47) times higher than in the general population (p-value = 1.0E-47) and tumor arose 50 years earlier. The XP-C group was at the highest risk for the 0-20 years old-patients (OR = 665; 95% CI 368-1200; p-value = 4.3E-30). The highest risks were observed for tumors of central nervous system (OR = 331; 95% CI 171-641; p-value = 2.4E-20), hematological malignancies (OR = 120; 95% CI 77-186; p-value = 3.7E-36), thyroid (OR = 74; 95% CI 31-179; p-value = 1.2E-8) and gynecological tumors (OR = 91; 95% CI 42-193; p-value = 3.5E-12). The type of mutation on the XPC gene is associated with different classes of internal tumors. The majority of French XP-C patients (80%) are originated from North Africa and carried the XPC delTG founder mutation specific from the South Mediterranean area. The OR is extremely high for young (0-20 years) patients with more than 1300-fold increase for the French XPs carrying the founder mutation.
CONCLUSION
Because the age of XP population is increasing due to better sun-protection and knowledge of the disease, these results are of particular importance for the physicians to help in early prevention and detection of internal tumors in their XP patients. Few preventive blood analyses or simple medical imaging may help to better detect early cancer appearance in this population.
Identifiants
pubmed: 35246173
doi: 10.1186/s13023-022-02203-1
pii: 10.1186/s13023-022-02203-1
pmc: PMC8896305
doi:
Substances chimiques
DNA-Binding Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
104Informations de copyright
© 2022. The Author(s).
Références
Jpn J Cancer Res. 1987 Nov;78(11):1135-43
pubmed: 3121549
Hum Mutat. 2014 Jan;35(1):117-28
pubmed: 24130121
Proc Natl Acad Sci U S A. 2016 Mar 1;113(9):E1236-45
pubmed: 26884178
JAMA. 1969 Mar 17;207(11):2073-9
pubmed: 5818379
Genome Med. 2012 May 23;4(5):44
pubmed: 22621766
ILAR J. 2017 Jul 1;58(1):17-41
pubmed: 28838066
Br J Dermatol. 1992 Apr;126(4):372-4
pubmed: 1571258
Blood. 2019 Jun 20;133(25):2718-2724
pubmed: 30914417
Cancer Res. 1998 Oct 1;58(19):4402-9
pubmed: 9766670
Br J Dermatol. 1989 Dec;121(6):767-71
pubmed: 2611127
Carcinogenesis. 2006 Jan;27(1):84-94
pubmed: 16081512
DNA Repair (Amst). 2008 May 3;7(5):744-50
pubmed: 18329345
Arch Dermatol. 1987 Feb;123(2):241-50
pubmed: 3545087
Acta Haematol. 2013;129(2):121-5
pubmed: 23207728
Br J Health Psychol. 2019 Sep;24(3):668-686
pubmed: 31183946
J Eur Acad Dermatol Venereol. 2016 Nov;30(11):e157-e158
pubmed: 26551352
J Eur Acad Dermatol Venereol. 2016 Oct;30(10):e42-e43
pubmed: 26446056
Carcinogenesis. 1984 Apr;5(4):511-4
pubmed: 6705149
Br J Dermatol. 1985 Nov;113(5):632-3
pubmed: 4063200
Scand J Urol Nephrol. 1997 Dec;31(6):569-71
pubmed: 9458518
J Invest Dermatol. 2009 Feb;129(2):502-6
pubmed: 18685619
Orphanet J Rare Dis. 2011 Nov 01;6:70
pubmed: 22044607
Nat Commun. 2020 Nov 17;11(1):5834
pubmed: 33203900
J Eur Acad Dermatol Venereol. 2020 Oct;34(10):2392-2401
pubmed: 32239545
Ann Intern Med. 1974 Feb;80(2):221-48
pubmed: 4811796
Nat Rev Cancer. 2005 Jul;5(7):564-73
pubmed: 16069818
N Engl J Med. 2009 Oct 8;361(15):1475-85
pubmed: 19812404
Mech Ageing Dev. 2008 Jul-Aug;129(7-8):492-7
pubmed: 18336867
Br J Dermatol. 2005 Mar;152(3):545-51
pubmed: 15787826
J Biol Chem. 2003 May 23;278(21):18767-75
pubmed: 12644471
Br J Dermatol. 2016 Feb;174(2):439-43
pubmed: 26211814
J Invest Dermatol. 2010 Jun;130(6):1537-42
pubmed: 20054342
Toxicol Sci. 2015 Feb;143(2):242-55
pubmed: 25628402
Br J Dermatol. 2013 May;168(5):1109-13
pubmed: 23278166
Int J Dermatol. 1999 Jul;38(7):520-4
pubmed: 10440281
Hum Mutat. 2003 Mar;21(3):217-28
pubmed: 12619107
J Endocrinol Invest. 2021 Jul;44(7):1475-1482
pubmed: 33155181
Cancer Res. 1977 Jun;37(6):1786-93
pubmed: 192462
Arch Esp Urol. 1989 Jun;42(5):484-6
pubmed: 2817979
Dermatologica. 1958 Jan;116(1):27-35
pubmed: 13523978
Br J Plast Surg. 1965 Jul;18:314-22
pubmed: 14327059
Int J Cancer. 1999 May 5;81(3):345-50
pubmed: 10209947
J Am Acad Dermatol. 1992 Jan;26(1):75-8
pubmed: 1732340
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Haematologica. 2020 Apr;105(4):e144-e146
pubmed: 31439674
EMBO J. 2006 Sep 20;25(18):4305-15
pubmed: 16957781
Arch Pediatr. 2016 Jan;23(1):75-7
pubmed: 26655364
Nat Rev Mol Cell Biol. 2008 Dec;9(12):958-70
pubmed: 19023283
J Med Genet. 2011 Mar;48(3):168-76
pubmed: 21097776
Genet Mol Biol. 2020 Mar 02;43(1 suppl. 1):e20190104
pubmed: 32141475
J Dermatol. 2019 Mar;46(3):e80-e81
pubmed: 30101995
DNA Repair (Amst). 2011 Jun 10;10(6):577-85
pubmed: 21482201